---
schema_version: "secwatch.filing_event.v1"
accession: "0001680367-22-000014"
form_type: "8-K"
ticker: "STTK"
cik: "0001680367"
company_name: "Shattuck Labs, Inc."
filed_at: "2022-05-12T23:59:59+00:00"
generated_at: "2026-06-25T18:40:33.791656+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Shattuck Labs Q1 net loss $24.5M ($0.58/shr); cash $239.2M; SL-172154 dose escalation ongoing

## Summary
- Net loss $24.5M ($0.58 per share) vs $11.8M ($0.28) YoY; R&D expenses $19.2M, up from $10.3M.
- Cash & short-term investments $239.2M as of Mar 31, 2022, down from $321.2M a year ago; runway into 2H2024.
- Phase 1 dose escalation of SL-172154 in ovarian cancer continues; full monotherapy data expected 1H2023.
- Combination trial of SL-172154 with liposomal doxorubicin in ovarian cancer on track to start 2H2022.
- Phase 1 trial of SL-279252 in solid tumors enrolling; top-line data expected 2H2022.

## SEC filing metadata
- accession: 0001680367-22-000014
- form_type: 8-K
- ticker: STTK
- cik: 0001680367
- company_name: Shattuck Labs, Inc.
- filed_at: 2022-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680367/000168036722000014/0001680367-22-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680367/000168036722000014/sttk-20220512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001680367-22-000014
- JSON: https://secwatch.observer/filing/0001680367-22-000014.json
- Plain text: https://secwatch.observer/filing/0001680367-22-000014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.